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SUMMARY 
Elderly people are more glucose intolerant and insulin resistant than young individuals, and many of them will 
develop type 2 diabetes. It remains, however, controversial whether this decrease in function is due to an 
inevitable consequence of "biological aging" or due to environmental or lifestyle variables. Indeed, increased 
adiposity/altered fat distribution, decreased fat free mass/abnormal muscle composition, poor dietary habits and 
physical inactivity all contribute to reduce insulin sensitivity. Insulin resistance in elderly people appears to 
predominate in skeletal muscle, whereas hepatic glucose output seems to be almost unaffected. Several 
abnormalities in islet β-cell and insulin secretion were also pointed out in elderly people such as increased 
amyloid deposition and decreased amylin secretion, impaired insulin secretion pulsatility, decreased insulin 
sensitivity of pancreatic β-cells to insulinotropic gut hormones and diminished insulin response to non-glucose 
stimuli such as arginine. Controversial results were reported concerning the effects of aging on absolute insulin 
secretion in response to oral or intravenous glucose. However, insulin secretion appears to decrease with age, 
with significantly diminished β-cell sensitivity and acute insulin response to glucose, provided it is analyzed 
relative to concomitant decreased insulin sensitivity. Thus, there is an interplay between decreased insulin 
secretion and increased insulin resistance that largely explains the abnormal glucose metabolism seen in elderly. 
Weight loss, especially reduction of abdominal adiposity, and increased physical activity may contribute to 
improve insulin sensitivity and glucose tolerance, and prevent the development of type 2 diabetes in elderly 
people. 
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RESUME 
Le diabète du sujet âgé : insulinorésistance et/ou altération de la sécrétion d'insuline ? 
Les sujets âgés sont plus intolérants au glucose et davantage insulino-résistants que les sujets jeunes, et nombre 
d'entre eux vont développer un diabète de type 2. Le fait de savoir si cette diminution fonctionnelle est la 
conséquence inéluctable du vieillissement biologique ou est secondaire à des modifications liées à 
l'environnement et au style de vie fait toujours l'objet de controverses. En effet, une augmentation de l'adiposité 
et/ou une anomalie de la distribution de la masse grasse, une diminution de la masse musculaire et/ou une 
altération de la composition du muscle squelettique, enfin, de mauvaises habitudes alimentaires et un manque 
d'activité physique sont tous des facteurs qui contribuent à réduire la sensibilité à l'insuline. L'insulinorésistance 
des sujets âgés semble prédominer dans le muscle squelettique, alors que le débit glucose hépatique ne paraît 
guère affecté. Plusieurs anomalies ont été également mises en évidence en ce qui concerne la cellule β des îlots 
de Langerhans du pancréas et la sécrétion d'insuline chez les sujets âgés, avec une augmentation des dépôts 
d'amyloïde et une sécrétion réduite d'amyline, une altération de la sécrétion pulsatile d'insuline, une diminution 
de la sensibilité de la cellule β vis-à-vis des hormones digestives de type incrétine et une réduction de la réponse 
à des stimuli non glucosés comme l'arginine. Des résultats contradictoires ont été rapportés à propos des effets 
du vieillissement sur la réponse insulino-sécrétoire absolue en réponse à l'administration de glucose par voie 
orale ou intraveineuse. Cependant, il apparaît que l'insulinosécrétion diminue avec l'âge, avec en particulier une 
diminution de la sensibilité de la cellule β et de la réponse insulinique précoce au glucose, à condition d'analyser 
la réponse insulinosécrétoire en tenant compte de la diminution concomitante de la sensibilité à l'insuline. Il 
existe, en effet, une étroite interrelation entre la diminution de l'insulinosécrétion et l'augmentation de 
l'insulinorésistance et cet effet synergique explique l'essentiel des anomalies du métabolisme du glucose 
observées chez le sujet vieillissant. La perte de poids, en particulier la réduction de l'adiposité abdominale, et 
l'augmentation de l'activité physique peuvent contribuer à améliorer la sensibilité à l'insuline et la tolérance au 
glucose et donc à prévenir la survenue d'un diabète de type 2 chez les sujets âgés. 
Mots-clés : Diabète sucré ■ Insulinorésistance ■ Insulinosécrétion ■ Sujet âgé ■ Tolérance au glucose. 
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Aging is associated with a decline of many, if not all, human physiological functions. The reduction in whole-
body carbohydrate metabolism in the elderly is one of the hallmarks of the aging process, and substantial 
evidence shows that increasing age is associated with decreased glucose tolerance and type 2 diabetes [1-5]. The 
decline in glucose tolerance is reflected in NHANES III (Third National Health and Nutrition Examination) 
survey on the prevalence of diabetes and impaired fasting glucose and impaired glucose tolerance in US adults 
[6]. Comparison of the percentage of physician-diagnosed diabetes in middle-aged adults (40-49 years) and 
elderly adults (≥ 75 years) reveals an increase from 3.9% to 13.2%. In addition, the percentage of adults with 
undiagnosed diabetes (fasting plasma glucose ≥ 126 mg/dl) increased from 2.5% to 5.7% and with impaired 
fasting glucose (110-125 mg/dl) increased from 7.1% to 14.1%. Thus, approximately one third of the elderly 
adults in the USA have abnormal glucose metabolism. 
A significant decrease in glucose tolerance with increasing age can be demonstrated from all epidemiological 
studies. The glucose intolerance of aging is manifested primarily by an increase in the postprandial blood 
glucose response while fasting blood glucose levels are generally only modestly elevated. After 50 years, fasting 
blood glucose levels rise by 0.06 mmol/l per decade and 2-hour levels in an oral glucose tolerance test (OGTT) 
by 0.5 mmol/l [1]. Glucose intolerance is probably attributable to a multiplicity of causes such as poor diet, 
physical inactivity, decreased lean body mass, increased visceral adiposity, decreased relative insulin secretion 
and peripheral insulin resistance [7, 8]. A detailed review of the specific effects of aging on glucose homeostasis 
has recently been published in a number of relevant articles [9-13]. Molecular abnormalities that occur in elderly 
patients with diabetes have not been fully elucidated. The glucokinase gene is the glucose sensor of the β-cell. 
Theoretically, alterations in this gene could explain defects in insulin secretion, but it is not clear whether the 
function of this gene is impaired in older people with diabetes. Insulin-receptor tyrosine kinase activity has been 
reported to be altered in elderly people with diabetes and insulin resistance, but it is uncertain whether this is the 
cause or the result of the elevated glucose levels in these patients [4]. Finally, other metabolic defects have 
recently been defined in elderly patients with diabetes. It has been shown that non-insulin mediated glucose 
uptake was significantly impaired in elderly patients with type 2 diabetes [14], Such abnormality may be 
important as in normal subjects, approximately 50% of glucose uptake after a meal occurs as a result of non-
insulin-mediated glucose uptake. The present review focuses on the clinical evidence of a change with age in 
insulin sensitivity and insulin secretion, possibly independent of changes in other known factors. It also 
emphasizes the interplay between defects in insulin secretion and insulin action leading to a high prevalence of 
abnormal glucose tolerance and type 2 diabetes in the elderly population (Fig. 1). 
Insulin resistance 
Insulin resistance is defined as a reduction compared to the normal range in the rate of glucose disposal elicited 
by a given insulin concentration [15, 16]. In practice, insulin resistance is not measured directly, but several 
methods exist for the measurement of insulin sensitivity [17]. Insulin resistance in the older population has been 
documented using a variety of techniques, among which the euglycaemic hyperinsulinaemic clamp, the 
hyperglycaemic clamp and the minimal model technique. There is a large body of literature to suggest that aging 
causes a peripheral resistance to the action of insulin [9, 12, 18, 19]. Differences between young and old subjects 
remained present even when glucose disposal was expressed per kilogram of lean body mass, ruling out 
decreased lean body mass as a cause of the impaired glucose tolerance associated with aging. However, a large 
recent study analyzing euglycaemic insulin clamp data collected at 20 centers throughout Europe from 1,146 
healthy men and women with normal glucose tolerance, ranging in age from 18 to 85 years, concluded that age 
per se is not or only a weak cause of insulin resistance [20]. Another recent in vivo (OGTT) and in vitro (adipose 
tissue glucose uptake) study also suggested that aging per se does not influence glucose homeostasis, but this 
study compared middle-aged rather than elderly individuals with young subjects [21]. Thus, the respective roles 
of age per se and various confounding factors in the decrease of insulin action usually seen in older patients 
remain to be evaluated [12] (Table I). 
The mechanisms underlying the development of insulin resistance are multifactorial [8]. Aging is associated with 
an increase in body weight and fat mass, together with a loss of fat-free mass. It is also accompanied by 
alterations in the insulin signalling pathway [11, 12]. Abdominal fat and visceral adiposity are correlated with 
hyperinsulinaemia and insulin resistance. Dietary constituents have also been shown to modulate insulin 
sensitivity, especially in the elderly, with increased fat content and reduced amount of carbohydrates leading to 
insulin resistance [22]. Modifications of the changes in body composition with aging by diet [22] and exercise 
training [23] could delay the onset of insulin resistance. Lifestyle modifications including body weight loss and 
physical activity provide health benefits and functional gains, and should be promoted to increase insulin 
sensitivity and prevent glucose intolerance and type 2 diabetes mellitus in older adults [12]. 
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Figure 1: Illustration of the main abnormalities influencing insulin secretion and insulin sensitivity in elderly 
people. 
 
Table I:  Contributors, markers and possible mechanisms of defects in insulin action in elderly people. 
Contributors 
Increased total fat mass 
Increased abdominal (visceral) adiposity 
Reduced fat free mass (skeletal muscle) 
Abnormal muscle composition 





Increased fasting plasma insulin 
Increased post-glucose load late plasma insulin levels (OGTT 
Decreased insulin-mediated glucose disposal (clamp) 
Decreased SI index (IVGTT + MinMod) 
Preserved hepatic insulin sensitivity 
Potential mechanisms 
Decreased GLUT4 transporters 
Decreased IGF-1 
Decreased insulin-mediated increase in blood flow 
Decreased cellular insulin signalling 
 
Effect of age on hepatic glucose production 
Hepatic glucose production (HGP) plays a major role in glucose homeostasis, both in the fasting and in the 
postprandial states [24]. The role of the liver in the maintenance of plasma glucose level has been best evaluated 
with the hyper-insulinaemic euglycaemic clamp. Dose-response relationships between plasma insulin levels and 
HGP clearly demonstrate that, in non-diabetic subjects, the liver is exquisitely sensitive to insulin and HGP is 
completely suppressed at plasma insulin levels well below the commonly used insulin dose [17]. There is no 
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difference in either the basal HGP or the dose-response curve of its suppression by insulin between young and 
old individuals [25]. However, with low dose of insulin infusions, HGP is more rapidly suppressed in the elderly, 
perhaps due to a delayed suppression of endogenous insulin release in the older individuals. The European 
Group for the Study of Insulin Resistance (EGIR) reported a tendency (P = 0.10) for HGP to decline with 
increasing age, but any significance was completely lost when adjusted for lean body mass [26]. Furthermore, 
hepatic glucose output has been shown not to be increased in elderly patients with type 2 diabetes [27]. Thus, 
hepatic insulin resistance does not seem to play a significant role in decreased glucose tolerance of elderly 
people. 
Effect of age on muscle glucose utilization 
Skeletal muscle is the primary sink for insulin-mediated glucose uptake as adipose tissue is relatively inert and 
accounts for only 2-3% of glucose uptake. The majority of reports examining the role of age on glucose uptake, 
utilizing a variety of techniques [17], have demonstrated decreased muscular insulin sensitivity during 
hyperinsulinaemia [9, 11, 12, 18]. In the report by EGIR [20], age was associated with a significant decrease in 
insulin-mediated glucose disposal measured during a euglycaemic hyperinsulinaemic clamp in univariate 
analysis, but this effect was no longer significant when adjusted for BMI. Thus, this large multicentre study 
demonstrated that glucose uptake is not altered as a function of age per se. Despite the strength of the EGIR 
study, the issue of age-related insulin resistance is still controversial, because it has been argued that complete 
dose-response curves are necessary to resolve the issue. In a dose-response study [28], an age-associated 
decrease in glucose utilization was demonstrated with preservation of maximal glucose uptake (i.e. shift of the 
dose-response curve to the right), and this relationship remained when the glucose utilization was plotted per 
kilogram of lean body mass. This study is in agreement with other studies where several insulin doses were 
employed [29, 30]. In addition, studies using various techniques, including the hyperglycaemic clamp, the 
forearm glucose uptake technique and the intravenous glucose tolerance test assessed with the minimal model, 
have revealed resistance to insulin-induced glucose disposal in aged individuals [9, 11, 12, 18], However, it is 
obvious that, in addition to age, various factors may influence insulin sensitivity including fat mass, fat 
distribution, physical fitness and dietary composition, besides genetic factors. When all these factors are taken 
into account, it is not clear that age per se still has an independent effect on peripheral glucose uptake. 
Aging is associated with an increase in body weight and body fat and a loss of fat-free mass. The body fat 
accumulation is particularly evident in the abdominal region. The amount of intra-abdominal fat is directly 
correlated with glucose intolerance and severity of insulin resistance, even after controlling for obesity [31]. In 
addition, insulin resistance is more closely associated with abdominal adiposity than with age [32, 33]. 
Collectively, these data support a relationship between abdominal obesity and the development of insulin 
resistance in the elderly. A large body of evidence shows that even a modest to moderate body weight loss (5-
10% of initial body weight) increases insulin sensitivity and improves glucose tolerance in obese individuals as 
well as in those with impaired glucose tolerance or type 2 diabetes [12, 34]. 
Besides central obesity, there has been recent interest in perturbations in skeletal muscle and their role in insulin 
sensitivity and glucose homeostasis [35]. Reduced attenuation of muscle in computerized tomography is largely 
the result of increased fat content in and around muscle fibres. Insulin-stimulated glucose uptake is negatively 
correlated with low density lean tissue [35], and lean tissue with a density below the normal range increases with 
age [36]. Thus, reduced attenuation of muscle may be another body composition characteristic important in the 
development of insulin resistance, but to date no study has supported this notion in the elderly [12]. 
In addition to insulin-stimulated glucose uptake in skeletal muscle, a second mechanism whereby glucose uptake 
increases in muscle is by muscle contraction. This process may involved adenosine 5'-monophosphate-activated 
protein kinase (AMPK). Increased recruitment of the AMPK signalling system by exercise (or drugs) may 
correct insulin resistance in patients with impaired glucose tolerance or type 2 diabetes mellitus resulting from 
defects in the insulin signalling cascade [37]. Lack of physical exercise frequently observed in elderly people 
may thus contribute to insulin resistance, and this may be improved with an aerobic exercise training programme 
[12, 23]. Such exercise-related improvement occurs with [38] or without [39] changes in body weight or fat 
mass, and improved insulin sensitivity may be accompanied by a reduction of β-cell secretory capacity without a 
change in glucose tolerance [23]. 
Various mechanisms have been proposed to explain insulin resistance in elderly people. GLUT-4 protein is the 
major isoform in skeletal muscle responsible for insulin-stimulated glucose uptake. Although muscle GLUT-4 
protein is unaltered in obesity and type 2 diabetes, levels of GLUT-4 decline with age, and are directly related to 
insulin sensitivity in normal, nondiabetic controls [40]. This suggests that these transporters may contribute to 
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the insulin resistance observed with aging, possibly because of a decline in physical activity. Serum levels of 
insulin-like growth factor-1 (IGF-1) have been shown to be decreased in elderly people and such a reduction was 
correlated to insulin resistance in this population [41]. Finally, insulin is known to stimulate blood flow by an 
endothelium-dependent mechanism. Insulin-mediated blood flow is impaired with normal aging, and there is an 
even greater impairment in this parameter in elderly patients with diabetes [42, 43]. However, the role of the 
alteration in insulin-mediated vasodilatation in the insulin resistance that occurs with aging and diabetes remains 
uncertain. 
Impaired insulin secretion 
It has been long recognized that amyloid deposition is present in the pancreas of older diabetic patients and 
amylin may play a role in decreasing insulin secretion in elderly patients with type 2 diabetes [44]. Age-related 
insulin secretory dysfunction may have a role in the alterations in glucose metabolism with age and may 
contribute to the high rates of glucose intolerance in the older population [13]. One challenge in studying the 
time course of development of abnormal glucose tolerance in any population, and especially in the elderly 
population, is the sensitivity of tests to detect early abnormalities of β-cell function [45]. The earliest insulin 
secretory defects in the progression from normal to abnormal glucose tolerance may be subtle. Thus, sensitive 
measures of β-cell function are crucial, as well as the appropriate assessment of insulin secretion regarding 
possible concomitant diminished insulin sensitivity [46] (Table II). 
The effect of age on β-cell sensitivity to glucose 
Many studies have used insulin levels in response to an OGTT to assess insulin secretion. Although the OGTT is 
standardized, simple to perform, and widely used, the β-cell stimulus is complex (including not only glucose but 
gastrointestinal and neural factors) and variable over time. Thus, studies using the OGTT are difficult to interpret 
in light of the low sensitivity and specificity of insulin levels in response to oral glucose as a surrogate measure 
of pancreatic β-cell function. In addition, factors affecting insulin sensitivity, such as adiposity, may play a 
crucial role. Insulin levels in response to oral glucose load were found to decline significantly with age, after 
adjustments were made for body habitus (and thus indirectly for obesity-related insulin resistance) [47]. In 
addition, a delayed insulin response in the first hour after oral glucose load has been described in older people 
compared with young adults [48]. 
The frequently-sampled intravenous glucose tolerance test provides an assessment of both first- and second-
phase insulin release as well as insulin sensitivity. Absolute defects in acute insulin response to intravenous 
glucose related to age alone have not been clearly demonstrated in early studies [49, 50], despite older subjects 
being glucose intolerant (but not in the diabetic range). In a more recent study [51], when subjects were 
classified by glucose tolerance status, older individuals with impaired glucose tolerance were insulin-resistant 
and tended to have lower acute insulin response to glucose and lower glucose effectiveness compared with older 
people with normal glucose tolerance. 
The hyperglycaemic clamp is a valuable technique to assess β-cell function, because it allows to nicely 
discriminate between early and late insulin responses. Previous studies using this method have shown little or no 
decrease in insulin secretion with age [29, 52-54]. However, none of these studies took into account the effect of 
age-related insulin resistance on β-cell function (see below). 
Finally, in a study using a stepped glucose infusion and C-peptide kinetics, no age difference was found in 
absolute insulin secretion rates [53]. However, this study suggested a decreased relative insulin response to 
stepped glucose infusion in old subjects when differences in glucose levels and insulin sensitivity between old 
and young subjects were considered. 
The effect of age on β-cell response to non-glucose stimuli 
β-cell function can be evaluated using a nonglucose stimulus such as arginine. In a study examining arginine-
stimulated insulin response in young and old men, β-cell secretory capacity was 48% lower with arginine 
stimulus in the old subjects [50]. 
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Table II: Contributors, markers and possible mechanisms of defects in insulin secretion in elderly people. 
Please note that some markers were not consistently found in all studies. 
Contributors 
Poor dietary habits (increased fat, decreased carbohydrate) 
Concomitant drugs 
Markers 
Disturbed insulin pulsatility 
Increased plasma proinsulin and proinsulin/insulin ratio 
Decreased amylin secretion 
Decreased post-glucose load early plasma insulin levels (OGTT) 
Decreased (NS) early and late insulin response (hyperglycaemic clamp) 
Decreased acute insulin response to intravenous glucose (IVGTT) 
Decreased relative insulin response to stepped glucose infusion 
Decreased insulin response to non glucose stimuli (arginine) 
Decreased β-cell function relative to concomitant insulin resistance (various tests) 
Potential mechanisms 
Decreased age-related β-cell mass 
Increased pancreatic islet amylin deposition 
Decreased β-cell sensitivity to glucose 
Decreased β-cell sensitivity to gut incretin hormones 
 
The effect of age on insulin processing 
An increased circulating proinsulin-to-insulin ratio in response to oral glucose challenge has been described in 
older adults [55]. However, these results were not confirmed in another study performed in old and young 
subjects matched for body mass index (BMI), showing similar proinsulinaemia in response to intravenous 
glucose and arginine [56]. Therefore, it is doubtful that a possible alteration in insulin processing inside the β-
cell could represent a major predisposing factor to the development of glucose intolerance in the elderly 
population. Finally, an interesting observation reported that the release of the β-cell peptide amylin is reduced in 
older subjects, a finding in agreement with decreased β-cell function in elderly [57]. 
The effect of age on insulin pulsatility 
Normal insulin secretion is pulsatile and orderly, with both rapid, low-amplitude pulses, which occur every 8-15 
min, and ultradian pulses, which have a larger amplitude and occur every 60-140 min. In the fasting state, older 
subjects have been found to have more disorderly insulin release, with decreased amplitude and mass of rapid 
insulin pulses and reduced frequency of ultradian pulses compared with young subjects [58]. In response to a 10-
h sustained glucose infusion, old subjects displayed reduced frequency, amplitude, and regularity of ultradian 
pulses compared with young subjects matched for BMI [59]. We evaluated insulin response to a 53-h constant 
glucose infusion in weight-matched young and old subjects [60]. The elderly subjects had decreased pulse 
amplitude and decreased responsiveness of insulin secretion to oscillations in plasma glucose. Alterations in the 
ultradian oscillations of insulin secretion in aging were related to a partial breakdown in the negative feedback 
loop between insulin secretion and glucose, mainly due to decreased β-cell responsiveness in older people [60], 
The slowing of the rapid insulin oscillations has been shown to participate in the abnormalities of glucose and 
lipid metabolism in the elderly [61]. The analogy between the abnormalities seen in older healthy adults and 
those reported in patients with type 2 diabetes suggests that alterations in oscillations in insulin secretion could 
represent an early defect causing decreased glucose tolerance in aging. 
The effect of age on incretin β-cell potentiation 
The enteroinsular axis refers to the glucose-stimulated gut hormones, or incretin hormones, that potentiate 
insulin release. Age-related alteration in the incretin hormones, including glucose-dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), has been of interest as a possible contributing factor to 
the impaired insulin secretion and the glucose intolerance seen with advancing age. Basal and post-oral glucose 
load GIP and GLP-1 levels have been found to be unchanged or increased in healthy old people compared with 
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young controls [62-64], Furthermore, exogenous infusion of GIP demonstrated that the potentiation of insulin 
response caused by GIP was greater in the young subjects than in the old during moderate hyperglycaemia [65]. 
These observations suggest that β-cell sensitivity to incretin hormones may be impaired in old people compared 
with younger controls. It has been hypothesized that this age-related impairment of insulin secretion to 
insulinotropic hormones, GIP and GLP-1, contributes to a reduction in glucose tolerance in elderly people [62]. 
Interplay between insulin sensitivity and insulin secretion 
Type 2 diabetes, also the form commonly observed in elderly people, is characterized by a defect in both insulin 
action and insulin secretion [8, 66, 67]. Lean elderly patients with type 2 diabetes have a profound impairment in 
glucose-induced insulin release but only mild resistance to insulin-mediated glucose disposal, whereas obese 
elderly patients with type 2 diabetes have adequate circulating insulin levels but marked resistance to insulin-
mediated glucose disposal [25]. In a careful study assessing pancreatic islet function by C-peptide measurements 
and kinetics, no age differences were found in absolute insulin secretion between young and old non diabetic 
individuals [53]. However, this study suggested a decreased relative insulin response to stepped intravenous 
glucose infusion in old subjects when differences in glucose levels and insulin sensitivity between old and young 
subjects were considered. 
There is a dynamic interaction between insulin secretion and insulin action: the hyperbola that describes the 
relationship between insulin sensitivity and insulin release implies that a feedback loop governs the interaction 
between the β-cell and the insulin-sensitive tissues [46]. Potential explanations for variable results when aging-
related defects in β-cell function are assessed include differences in age-related variables, not only obesity 
(abdominal adiposity) and physical activity, but also insulin resistance. The product of insulin sensitivity and the 
insulin response provides a true measure of β-cell function, rather than the insulin or C-peptide response 
examined in isolation. The product of insulin sensitivity and the acute insulin response to intravenous glucose, 
called the disposition index, is constant in individuals with normal glucose tolerance [46]. Older subjects, as 
other individuals at high risk to develop type 2 diabetes, have been shown to have β-cell dysfunction, manifest as 
a first-phase insulin response to intravenous glucose that is reduced relative to the degree of insulin sensitivity, 
thus leading to a decreased disposition index [23,46,68]. When young and old subjects are matched for variables 
affecting insulin sensitivity, reduced β-cell function with aging has been detected, with reduction by 46 % of 
acute insulin response to intravenous glucose [68] and reduction by 56 % of second-phase insulin secretion [69]. 
To assess β-cell compensation to the insulin resistance of aging, β-cell function was measured both as the acute 
ability of glucose to directly stimulate the pancreatic β-cells to secrete insulin (AIR glucose) and as the ability of 
glucose to potentiate the β-cell insulin response to arginine (AIRmax) in groups of young and older subjects 
[56]. β-cell function is reduced in older subjects when the degree of insulin sensitivity is taken into account 
(decreased SI x AIRglucose and SI x AIRmax). The product of SI and fasting insulin was also significantly 
lower in the older subjects than in the young, and the hyperbolic fit for the relation between SI and IRI was 
significantly different between the younger and older subjects. These data suggest that although aging does not 
affect the hyperbolic relationship between insulin sensitivity and fasting insulin, it appears to change the 
quantitative interaction, with lower β-cell compensation in older subjects. 
Conclusion 
The development of glucose intolerance has been well established to be a part of the human aging process. This 
change in glucose metabolism has been shown to be due to diminished sensitivity to insulin at its target tissues, 
especially skeletal muscle, and to inappropriately low pancreatic β-cell function. Thus, both insulin resistance 
and reduced compensation in β-cell function explain the higher risk of impaired glucose tolerance and type 2 
diabetes in older individuals. Lifestyle modifications including body weight loss and regular physical activity 
provide health benefits and functional gains, and should be promoted to increase insulin sensitivity and prevent 
or improve glucose intolerance and type 2 diabetes mellitus in older adults. 
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